Clinical trials Brief October 2, 2026, 4:59 AM ET

Results posted for phase 3 orforglipron study in type 2 diabetes

Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study enrolled 546 participants and completed primary data collection on September 15, 2025.

Primary source

ClinicalTrials.gov results record, October 1, 2026

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Read the source: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation